利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

50 条记录 (耗时 0.038 秒)

    Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
    4.
    发明授权
    Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease 有权
    人源化抗CD22抗体及其在治疗肿瘤，移植和自身免疫疾病中的应用

    公开(公告)号：US07829086B2

    公开(公告)日：2010-11-09

    申请号：US11715308

    申请日：2007-03-06

    申请人： David M. Hilbert ,  Tarran Jones ,  David G. Williams

    发明人： David M. Hilbert ,  Tarran Jones ,  David G. Williams

    IPC分类号： A61K39/395 ,  C07K16/18 ,  C07H21/04

    CPC分类号： C07K16/2803 ,  A61K2039/505 ,  C07K16/465 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/92

    摘要： The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework regions of the immunoglobulin light chain variable region (“VK”). The invention further comprises heavy and/or light chain FW regions that contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. Human or humanized VH framework regions of antibodies of the invention may comprise one or more of the following residues: a valine (V) at position 24 of framework region 1, a glycine (G) at position 49 of framework region 2, and an asparagine (N) at position 73 of framework region 3, numbered according to Kabat. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD22 antigen and that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.

    摘要翻译： 本发明提供抗CD22小鼠单克隆抗体HB22.7的嵌合和人源化形式。 本发明的抗CD22抗体包含免疫球蛋白重链可变区（“VH”）和免疫球蛋白轻链可变区（“VK”）的四个人或人源化框架区的四个人或人源化框架区。 本发明还包含含有一个或多个反向突变的重链和/或轻链FW区，其中人FW残基被交换为亲本小鼠重链或轻链中存在的相应残基。 本发明抗体的人源化或人源化VH框架区可以包含一个或多个以下残基：构架区1的位置24的缬氨酸（V），构架区2的位置49处的甘氨酸（G）和天冬酰胺 （N）在框架区域3的位置73，根据Kabat编号。 本发明进一步涉及药物组合物，免疫治疗组合物和使用结合人CD22抗原并且优选介导人ADCC，CDC和/或细胞凋亡的治疗性抗体的方法：治疗人类受试者的B细胞疾病和病症， 例如但不限于B细胞恶性肿瘤，用于治疗和预防自身免疫疾病，以及用于治疗和预防移植物抗宿主病（GVHD），体液排斥和移植后淋巴增生性疾病的人类移植 收件人

    Humanized immunoglobulin reactive with α4β7 integrin
    6.
    发明授权
    Humanized immunoglobulin reactive with α4β7 integrin 有权
    人源化免疫球蛋白与α4β7整合素反应

    公开(公告)号：US07402410B2

    公开(公告)日：2008-07-22

    申请号：US11511164

    申请日：2006-08-28

    申请人： Paul D. Ponath ,  Douglas J. Ringler ,  S. Tarran Jones ,  Walter Newman ,  José Saldanha ,  Mary M. Bendig

    发明人： Paul D. Ponath ,  Douglas J. Ringler ,  S. Tarran Jones ,  Walter Newman ,  José Saldanha ,  Mary M. Bendig

    IPC分类号： C12N15/13 ,  C12N15/63 ,  C12N5/10 ,  C12P21/04

    CPC分类号： C07K16/2839 ,  A61K38/00 ,  C07K14/70503 ,  C07K2317/24 ,  C07K2319/00

    摘要： The present invention relates to isolated nucleic acids encoding humanized immunoglobulins having binding specificity for α4β7 integrin, isolated nucleic acids encoding a humanized immunoglobulin heavy chain and isolated nucleic acids encoding a humanized light chain having binding specificity for α4β7 integrin. The invention also relates to expression vectors and host cells comprising a nucleotide sequence which encodes a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7. The invention further relates to methods of preparing a humanized immunoglobulin, humanized immunoglobulin heavy chain and humanized immunoglobulin light chain that has binding specificity for α4β7 integrin.

    摘要翻译： 本发明涉及编码对α4β7整联蛋白具有结合特异性，编码人源化免疫球蛋白重链的分离的核酸和编码具有α4β7整联蛋白的结合特异性的人源化轻链的分离的核酸的分离的核酸。 本发明还涉及包含编码具有对α4β7具有结合特异性的人源化免疫球蛋白或其抗原结合片段的核苷酸序列的表达载体和宿主细胞。 本发明还涉及制备对α4β7整联蛋白具有结合特异性的人源化免疫球蛋白，人源化免疫球蛋白重链和人源化免疫球蛋白轻链的方法。